Article
Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate.
Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2025
Hess Gabriel F, Ercan Caner, Wilhelm Alexander, Zeindler Jasmin, Coto-Llerena Mairene, Däster Silvio, Muenst Simone, Vosbeck Jürg, Di Tommaso Luca, Bolli Martin, Terracciano Luigi M, Kollmar Otto, Piscuoglio Salvatore, Soysal Savas D
Abstract excerpt
INTRODUCTION: Curative treatments in early-stage hepatocellular carcinoma (HCC) are limited by high recurrence rates, and targeted therapies against HCC are rare. Tumour microenvironment (TME) plays a crucial role. One strategy is the expression of programmed cell death receptor 1 ligand (PD-L1), whose receptor PD-1 is expressed on activated T cells. The use of immune checkpoint inhibitors (ICIs) has shown...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Programmed Cell Death 1 Receptor